Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replimune Group Inc REPL

Healthcare Biotechnology
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a... see more

Recent & Breaking News (NDAQ:REPL)

Replimune Announces Pricing of Upsized Public Offering

GlobeNewswire 4 hours ago

Replimune Announces Proposed Public Offering

GlobeNewswire 21 hours ago

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

GlobeNewswire 4 days ago

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire 13 days ago

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

GlobeNewswire November 9, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 8, 2024

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

GlobeNewswire October 30, 2024

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire October 9, 2024

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire October 1, 2024

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire September 15, 2024

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

GlobeNewswire September 9, 2024

Stockholders Vote to Elect Madhavan Balachandran to Board of Directors

GlobeNewswire September 5, 2024

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

GlobeNewswire August 22, 2024

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

GlobeNewswire August 13, 2024

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2024

Replimune to Present at Two Upcoming Investor Conferences

GlobeNewswire July 30, 2024

Replimune Announces $100 Million Private Placement Financing

GlobeNewswire June 13, 2024

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 7, 2024

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

GlobeNewswire June 6, 2024

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

GlobeNewswire June 3, 2024